Saurabh Sewak, PhD joined Foghorn Therapeutics in 2022 as vice president, corporate development, to lead commercial strategy, and support business development and corporate strategy.
Saurabh joins from his advisory firm, Sewaa Strategies, where he advised small biotech companies in corporate development, commercial strategy, portfolio, and alliance management. Prior to this, he was the Chief of Staff to the CEO and Head of Strategy for North America at Ipsen. He led strategic, operational, and cultural change initiatives including the post-merger integration of Clementia Pharma. He also led the MSL organization for neuroscience and rare diseases. Before Ipsen, Saurabh led commercial development at Tesaro (now GSK) where he was responsible for expanding the footprint of the PARP inhibitor, ZEJULA™, and crafting the development strategy for the PD-1 inhibitor, JEMPERLI™. He has also held leadership roles in commercial, strategy and business development at Biogen.
Saurabh was elected to the board of the Leukemia & Lymphoma Society in 2021, and in 2022 he was elected as the vice chair of the board. Saurabh is a pharmacist by primary training and holds a PhD in pharmaceutical sciences from the University of Mississippi.